Voronoi In Spotlight For Brain-Permeable Lung Cancer Candidate

Korean Venture Building Platforms, Eyes IPO

South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.

Digital illustration of lung cancer cells in color background - Illustration
Will Voronoi's NSCLC Drug Candidate Hit A Home Run? • Source: Shutterstock

Voronoi Inc.'s business development team is having the busiest time since its establishment after the South Korean bioventure presented results for its novel non-small cell lung cancer (NSCLC) drug at the recent American Association for Cancer Research (AACR) meeting.

“So many people have gathered at our booth and shown interest to our poster session at the AACR and multiple...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia